RFCA
JAZZ icon

R&F Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

R&F Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,103
Closed -$774K – 755
2016
Q4 		$774K Buy
+7,103
New +$791K 0.27% 107

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

R&F Capital Advisors's JAZZ Position: Q1 2017 in Review

R&F Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 7,103 shares — an estimated $774K sold.

R&F Capital Advisors first reported a position in JAZZ in Q4 2016 and held it in 1 quarter. The position peaked at $774K in Q4 2016. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

  • R&F Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 7,103 Jazz Pharmaceuticals shares in Q1 2017, an estimated $774K.
  • R&F Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Jazz Pharmaceuticals position peaked at $774K in Q4 2016.
  • 306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.